(CNBS) Seymour Cannabis - Overview
Etf: Cannabis, Hemp, US, Stocks, Cannabis Ecosystem
| Risk 5d forecast | |
|---|---|
| Volatility | 80.5% |
| Relative Tail Risk | -16.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.52 |
| Alpha | -2.52 |
| Character TTM | |
|---|---|
| Beta | 0.705 |
| Beta Downside | 1.005 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.41% |
| CAGR/Max DD | -0.20 |
Description: CNBS Seymour Cannabis January 05, 2026
Amplify Seymour Cannabis ETF (NYSE ARCA: CNBS) is a non-diversified U.S. ETF that commits at least 80 % of its net assets (plus any investment-purpose borrowings) to securities of companies that generate ≥50 % of revenue from the domestic cannabis and hemp ecosystem, as selected by Amplify Investments. The fund’s mandate also permits derivatives that mimic the economic profile of those securities, aiming to capture growth in a sector still constrained by federal policy.
Key metrics as of the most recent filing: the ETF holds roughly 30 – 35 constituents, with a weighted average expense ratio of 0.70 % and an assets-under-management (AUM) of about $150 million. The U.S. cannabis market is projected to reach $45 billion in 2026, driven by expanding state-level legalization and the emergence of hemp-derived CBD products, while federal-level policy uncertainty remains the primary risk factor. Recent earnings reports from leading holdings show average revenue growth of 18 % YoY, reflecting strong consumer demand and improving distribution channels.
For a deeper, data-driven view of CNBS’s risk-adjusted performance and sector exposure, you may find ValueRay’s analytical dashboard worth exploring.
What is the price of CNBS shares?
Over the past week, the price has changed by +2.17%, over one month by -12.05%, over three months by -10.07% and over the past year by +14.58%.
Is CNBS a buy, sell or hold?
What are the forecasts/targets for the CNBS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 23.2 | -8.9% |
CNBS Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 88.7m USD (88.7m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 88.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 88.7m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.51% (E(88.7m)/V(88.7m) * Re(8.51%) + (debt-free company))
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)